Crestchem Limited Announces FY26 Financials, Recommends Dividend

Revenue from operations for the year ended March 31, 2026, stood at ₹29.61 crore.
Profit for the period was ₹2.71 crore.

Reader Takeaway: Revenue growth of 18% is positive, while a stable dividend provides shareholder returns amidst early-stage subsidiary formation.

What just happened

Crestchem Limited has released its audited financial results for the fiscal year ended March 31, 2026. The company reported a revenue of ₹29.61 crore, marking an 18.06% increase from ₹25.08 crore in the previous fiscal year. Net profit for the period remained largely stable at ₹2.71 crore, a slight decrease of 0.48% from ₹2.73 crore in FY25. Earnings per share (EPS) also saw a marginal decline from ₹9.09 to ₹9.03.

Additionally, the board has recommended a final dividend of ₹1.50 per equity share (15% of the face value) for FY26, subject to shareholder approval. The company also announced the incorporation of a new subsidiary, Oleo Biosciences Private Limited, on March 31, 2026, in which Crestchem holds a 75% stake. An investment of up to ₹2.25 crore has been approved for this subsidiary.

Why this matters

The revenue growth indicates expanding business operations. The recommended dividend offers direct financial returns to shareholders. The formation of Oleo Biosciences signals a strategic move towards diversification or expansion into new areas, although it is currently in its nascent stage without commercial operations.

The backstory

In the previous fiscal year (FY25), Crestchem had reported revenues of ₹25.08 crore and a net profit of ₹2.73 crore. The company has consistently focused on its core chemical business. The formation of Oleo Biosciences marks a significant new development in its corporate strategy, moving beyond its traditional focus.

What changes now

Investors can anticipate direct returns through the proposed dividend. The company's focus will likely broaden to include the development and operationalization of Oleo Biosciences. This new venture will require monitoring for its potential contribution to future revenues and profitability. The board has also approved the reappointment of key directors, ensuring management continuity.

Risks to watch

The slight decrease in net profit despite revenue growth warrants attention. The success and profitability of the new subsidiary, Oleo Biosciences, remain unproven as it has yet to commence commercial operations. The planned investment in the subsidiary should be tracked for its effective utilization.

Peer comparison

Information on specific peers and their recent financial performance or diversification strategies is not provided in the filing, making a direct comparison difficult based solely on this announcement.

Context metrics (time-bound)

• Revenue Growth: +18.06% (FY26 vs FY25)
• Profit Change: -0.48% (FY26 vs FY25)
• Dividend Recommendation: ₹1.50 per share (FY26)
• Subsidiary Stake: 75% in Oleo Biosciences Private Limited
• Subsidiary Investment Approval: Up to ₹2.25 crore

What to track next

Shareholder approval of the proposed dividend. The progress and commencement of commercial operations for Oleo Biosciences Private Limited. Future financial results of Crestchem, particularly tracking the impact of the new subsidiary on overall performance.